No previous study reported the treatment outcome of stage III nasopharyngeal carcinoma (NPC) patients. The investigators try to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma Epstein-Barr virus (EBV) DNA assay for future therapy improvement.
The stage III NPC patients were the majority group of the patient population of NPC. But most clinical trials focused on the treatment of American Joint Committee on Cancer (AJCC) 7th edition stage IVA/IVB treatment for high risk of recurrence or metastasis. No previous study reported the treatment outcome of stage III NPC patients. The investigators tried to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma EBV DNA assay for future therapy improvement.
Study Type
OBSERVATIONAL
Enrollment
366
Overall survival (OS)
Diagnosis to death
Time frame: 5 year
Progression-free survival (PFS)
Diagnosis to death to recurrence or metastasis
Time frame: 5 year
Distant metastasis failure-free survival (DMFFS)
Diagnosis to death to distant metastasis
Time frame: 5 year
Locoregional failure-free survival (LRFFS)
Diagnosis to death to locoregional failure
Time frame: 5 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.